I think it depends on the company, AstraZeneca CEO already said a while ago they will be manufacturing this at cost or near cost, this is a time for big pharma

I think it depends on the company, AstraZeneca CEO already said a while ago they will be manufacturing this at cost or near cost, this is a time for big pharma to give back. Some drug companies like Gilead though have very high markup, paid by the taxpayer. And some bioteh companies with mRNA vaccines in phase 1/2 trials like Moderna and Biontech, or protein treatment like Synairgen have seen share prices skyrocket. I guess the assumption is they will be collecting fees from the IP and/or future contracts for other drugs if this works out.